Sarepta shares jump 13%, extending Monday’s surge on drug approval – CNBC


CNBC
Sarepta shares jump 13%, extending Monday’s surge on drug approval
CNBC
The drug was granted accelerated approval by the Food and Drug Administration and it treats patients with Duchenne muscular dystrophy, a rare, genetic muscle-wasting disease. Late Monday, the pharmaceutical firm announced in a conference call that the¬†…
Does Sarepta Therapeutics Inc.’s FDA Win Make Shares a Buy?Motley Fool
Sarepta shares surge 90% on FDA approvalFinancial Times
FDA grants accelerated approval to first drug for Duchenne muscular dystrophyFDA.gov
FDA
all 309 news articles >>

Source: shares – Google News

Sharing information is key – Share Dealing Business News UK. Social Commerce and Social Media Management playing a big part. Suaju Ltd